Clinical trial · Interventional
Macrophages Effect on Chemoresistance
Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Macrophages are derived from monocytes recruited to the tumor site and stimulated by specific chemokines secreted by tumor cells. These tumor associated macrophages (TAMs) have been postulated as being involved in the progression of cancer. Based on our preliminary findings and on published data we hypothesized that macrophage-induced chemoresistance (MIC) can promote survival of pancreatic carcinoma cells during chemotherapy. The overall goal of this study is to evaluate the mechanism of MIC in an in-vitro model of Pancreatic ductal adenocarcinoma (PDA). methods: 1. The human PDA cell line Panc1 will be grown in suitable conditions. 2. Macrophages will be produced by incubating mononuclear cells from the blood of healthy donors in medium with M-CSF for 7 days. 3. TAMs will be generated by culturing these macrophages with tumor-culture conditioning medium (TCCM) of PDA Cells for an additional 72 hours. 4. Human pancreatic cells (PANC1) will be treated with gemcitabine following exposure to macrophages CM. 5. Cell proliferation will be quantified by light microscopy and by an XTT Cell Proliferation Assay Kit.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| the Focus of the Study is Macrophage-induced Chemoresistance in Pancreatic Carcinoma Cells During Chemotherapy. | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| taking blood samples from healthy people | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- irrelevant
- interventionNames
- Procedure: taking blood samples from healthy people
Primary outcomes (1)
- measure
- proliferation and migration of PANC1 cell line in the tested groups.
- timeFrame
- one day to get the blood samples, and a year after that to complete the basic research
- description
- the macrophages will be isolated from the blood we'll get from the healthy volunteers. the outcome measure is related to the basic research and not clinical so there's no symptom/outcome related to the participants.
Secondary outcomes (1)
- measure
- To determine whether direct cell-to-cell interaction or soluble factors participate in MIC.
- timeFrame
- a year from obtaining the blood samples
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * healthy people Exclusion Criteria: * refusal to participate
References
Publications (0)
Data not yet available